Fungal CYP51 Inhibitors VT-1161 and VT-1129 exhibit strong in vitro activity against Candida glabrata and C. krusei isolates clinically resistant to azole and echinocandin antifungal compounds [PublishAheadOfPrint]

In vitro activity of fungal CYP51 inhibitors VT-1161 and VT-1129 was determined for Candida glabrata (N=34) and C. krusei (N=50). C. glabrata isolates were screened for FKS mutations. All isolates were resistant clinically and/or in vitro to one or more standard antifungal compounds. VT-1161 and VT-1129 MICs for all isolates were at least 5-fold below achievable human plasma levels for VT-1161. VT-1161 and VT-1129 are promising for treatment of resistant C. glabrata and C. krusei infections.

http://ift.tt/2hnc8vW